This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Pfizer Corporation. Active years: 2020-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020-2024
Title: Weidong Zhang: Innovator in MAdCAM Antagonist Treatments
Introduction
Weidong Zhang is a prominent inventor based in Acton, MA (US). He has made significant contributions to the field of medical treatments, particularly in the area of MAdCAM antagonists. With a total of 2 patents to his name, Zhang's work is paving the way for advancements in patient care.
Latest Patents
Zhang's latest patents focus on dosage regimens for MAdCAM antagonists. The first patent provides a method for treating patients by administering an initial dose of between about 1 mg and about 150 mg of a MAdCAM antagonist antibody. Additionally, biomarkers for assessing a patient's response to anti-MAdCAM treatment are included in this invention. This innovative approach aims to enhance the effectiveness of treatments for patients requiring MAdCAM antagonists.
Career Highlights
Weidong Zhang is currently employed at Pfizer Corporation, where he continues to develop groundbreaking medical solutions. His work at Pfizer has allowed him to collaborate with leading experts in the field, further enhancing the impact of his inventions.
Collaborations
Zhang has worked alongside notable colleagues such as Fabio Cataldi and Robert A Clare. These collaborations have contributed to the successful development of his patents and the advancement of medical treatments.
Conclusion
Weidong Zhang's contributions to the field of MAdCAM antagonists demonstrate his commitment to improving patient outcomes through innovative treatments. His work at Pfizer and his patented inventions are significant steps forward in medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
